Free Trial

Assertio (ASRT) Stock Price, News & Analysis

+0.01 (+0.66%)
(As of 09:29 AM ET)
Today's Range
50-Day Range
52-Week Range
1,324 shs
Average Volume
1.06 million shs
Market Capitalization
$145.53 million
P/E Ratio
Dividend Yield
Price Target

Assertio MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
191.9% Upside
$4.44 Price Target
Short Interest
9.79% of Shares Sold Short
Dividend Strength
News Sentiment
1.11mentions of Assertio in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$35,350 Bought Last Quarter
Proj. Earnings Growth
From ($0.13) to $0.11 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.02 out of 5 stars

Medical Sector

337th out of 901 stocks

Pharmaceutical Preparations Industry

153rd out of 426 stocks

ASRT stock logo

About Assertio Stock (NASDAQ:ASRT)

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

ASRT Stock Price History

ASRT Stock News Headlines

Kids trading options?
This AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)
Assertio Holdings, Inc. (NASDAQ:ASRT) Short Interest Update
Kids trading options?
This AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)
Assertio Names O'Grady CEO
See More Headlines
Receive ASRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$142.05 million
Cash Flow
$0.70 per share
Book Value
$1.46 per share


Free Float
Market Cap
$144.59 million
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

ASRT Stock Analysis - Frequently Asked Questions

How have ASRT shares performed this year?

Assertio's stock was trading at $1.07 on January 1st, 2024. Since then, ASRT stock has increased by 42.1% and is now trading at $1.52.
View the best growth stocks for 2024 here

How were Assertio's earnings last quarter?

Assertio Holdings, Inc. (NASDAQ:ASRT) posted its quarterly earnings data on Monday, May, 6th. The company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($0.01) by $0.04. The business earned $32.45 million during the quarter, compared to analyst estimates of $28.93 million. Assertio had a negative net margin of 234.40% and a positive trailing twelve-month return on equity of 10.80%.

Who are Assertio's major shareholders?

Assertio's top institutional shareholders include SummerHaven Investment Management LLC (0.17%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Daniel A Peisert, William Mckee, Heather L Mason, Jeff L Vacirca, Ajay Patel, Sam Schlessinger and Paul Schwichtenberg.
View institutional ownership trends

How do I buy shares of Assertio?

Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Assertio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Assertio investors own include Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN) and

This page (NASDAQ:ASRT) was last updated on 7/25/2024 by Staff

From Our Partners